Middle East branded generics market size, share, growth drivers, trends, opportunities & forecast 2025–2030

Middle East Branded Generics Market Overview

• The Middle East Branded Generics Market is valued at USD 19.7 billion, based on a five-year historical analysis. This growth is primarily driven by increasing healthcare expenditure, the rising prevalence of chronic and lifestyle diseases, and a growing demand for affordable medication options. The market is further supported by the expansion of healthcare infrastructure, government incentives for local manufacturing, and increasing acceptance of generics among healthcare professionals and patients. Recent trends also highlight the impact of localization policies and strategic collaborations between multinational and regional manufacturers, particularly in Saudi Arabia and the United Arab Emirates, which are fostering innovation and improving access to branded generics .
• Key players in this market include Saudi Arabia, the United Arab Emirates, and Turkey. These countries dominate the market due to robust healthcare systems, significant investments in pharmaceutical manufacturing, and regulatory reforms that encourage the production and distribution of branded generics. Additionally, increasing population, urbanization, and a rising burden of non-communicable diseases are driving demand for healthcare services and affordable pharmaceuticals .
• In 2023, the Saudi Food and Drug Authority (SFDA) implemented the “Guideline for Registration of Generic Drugs, 2023” issued by the Saudi Food and Drug Authority. This regulation mandates that all branded generics undergo stringent quality control processes, including bioequivalence studies and clinical evaluations, before approval. The guideline ensures that branded generics meet the same safety, efficacy, and quality standards as originator drugs, thereby strengthening consumer confidence and supporting broader adoption of generics in the region .

Middle East Branded Generics Market Segmentation

By Type:The market is segmented into four main types: Prescription Generics, Over-the-Counter (OTC) Generics, Biologics/Biosimilars, and Specialty Generics. Prescription Generics dominate the market, driven by a surge in patent expirations for branded drugs and increasing demand for cost-effective alternatives. OTC Generics are gaining traction as consumers become more health-conscious and prefer self-care solutions. Biologics/Biosimilars are emerging rapidly due to advancements in biotechnology and the growing prevalence of chronic diseases. Specialty Generics, while a smaller segment, address niche therapeutic needs and are supported by targeted innovation and regulatory incentives .

By Therapeutic Area:The market is categorized into several therapeutic areas, including Cardiovascular, Oncology, Diabetes, Central Nervous System (CNS), Anti-infectives, Respiratory, Dermatology, and Others. The Cardiovascular segment leads the market, reflecting the high prevalence of heart diseases and hypertension in the region. Oncology follows, driven by increasing cancer incidence and improved access to advanced therapies. Diabetes medications are in high demand due to the region’s rising rates of obesity and metabolic disorders. Other segments, such as CNS, anti-infectives, respiratory, and dermatology, are experiencing steady growth, supported by ongoing innovation and heightened awareness among healthcare providers and patients .

Middle East Branded Generics Market Competitive Landscape

The Middle East Branded Generics Market is characterized by a dynamic mix of regional and international players. Leading participants such as Hikma Pharmaceuticals, Sandoz (Novartis), Viatris (formerly Mylan N.V.), Teva Pharmaceutical Industries, Gulf Pharmaceutical Industries (Julphar), SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Tabuk Pharmaceuticals, Amman Pharmaceutical Industries, Pharma International Company (PIC), Dar Al Dawa Development & Investment Co., Eva Pharma, Arab Pharmaceutical Manufacturing Co., Jamjoom Pharma, Al-Dawaa Pharmacies, and AJA Pharma contribute to innovation, geographic expansion, and service delivery in this space.

Middle East Branded Generics Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Chronic Diseases:The Middle East is witnessing a significant rise in chronic diseases, with the World Health Organization reporting that non-communicable diseases account forover 70% of all deaths in the region. In future, an estimatedapproximately 25 million peoplein the Middle East will be living with diabetes, driving demand for affordable medications. This surge in chronic conditions necessitates a robust supply of branded generics, which are often more accessible than their branded counterparts, thus propelling market growth.
• Rising Healthcare Expenditure:Healthcare spending in the Middle East is projected to reachUSD 135 billion, according to the IMF. This increase is driven by government initiatives aimed at improving healthcare infrastructure and services. As healthcare budgets expand, there is a growing focus on cost-effective solutions, including branded generics, which offer quality medications at lower prices. This trend is expected to enhance the market's attractiveness to both consumers and healthcare providers.
• Expanding Health Insurance Coverage:The expansion of health insurance coverage across the Middle East is a critical growth driver for the branded generics market. In future, it is estimated that over60% of the populationwill have access to health insurance, up from45%. This increase facilitates greater access to medications, including generics, as insured patients are more likely to seek affordable treatment options. Consequently, this trend is expected to significantly boost the demand for branded generics in the region.

Market Challenges

• Intense Competition from Local and International Players:The branded generics market in the Middle East faces fierce competition, withover 200 local manufacturersand numerous international companies vying for market share. This saturation leads to price wars, which can erode profit margins. In future, the average price of branded generics is expected to decline by10%due to this competitive pressure, making it challenging for companies to maintain profitability while ensuring product quality.
• Regulatory Hurdles and Compliance Issues:Navigating the regulatory landscape in the Middle East poses significant challenges for branded generics manufacturers. Stricter quality control measures and compliance requirements are being enforced, with the average time for product approval increasing to18 months. This extended timeline can delay market entry and increase costs, hindering the ability of companies to respond swiftly to market demands and capitalize on emerging opportunities.

Middle East Branded Generics Market Future Outlook

The future of the Middle East branded generics market appears promising, driven by increasing healthcare investments and a growing emphasis on affordable medication. As governments prioritize healthcare reforms, the demand for branded generics is expected to rise, particularly in underserved areas. Additionally, advancements in technology and digital health solutions are likely to enhance distribution and accessibility, further supporting market growth. Companies that adapt to these trends will be well-positioned to thrive in this evolving landscape.

Market Opportunities

• Expansion into Emerging Markets:There is a significant opportunity for branded generics companies to expand into emerging markets within the Middle East. Countries like Iraq and Yemen, with growing populations and increasing healthcare needs, present untapped markets. In future, these regions are expected to see a15% increasein healthcare spending, creating a favorable environment for branded generics to flourish.
• Development of Innovative Drug Formulations:The demand for innovative drug formulations is on the rise, particularly in the context of personalized medicine. In future, the market for personalized medications in the Middle East is projected to reachUSD 5 billion. Companies that invest in R&D to develop tailored generics can capture a significant share of this growing segment, enhancing their competitive edge and market presence.